17 Kazia Theraputics Limited Annual Report 2022 2022 at a Glance Chairman’s Letter CEO’s Report Key Milestones Pipeline Review ESG Financial Reports DR CARLOS GOMEZ-ROCA Dr Carlos Gomez-Roca is CoChair of the Clinical Research Unit at IUCT-Oncopole in Toulouse, France, and leader in the Early Phase Unit with a focus on targeted therapies and immuno-oncology. His main research interests are early clinical development, phase I trials across solid tumours, innovative methods of evaluation of novel drugs’ clinical activity, personalised medicine and mechanisms of toxicities of new targeted agents and immunotherapies. Dr Gomez-Roca completed his medical training in 2000 at the University of Buenos Aires and trained as internal medicine specialist at Instituto Universitario CEMIC at Buenos Aires (Argentina) and obtained his degree with honours in 2005. He continued his training in Medical Oncology and obtained his diploma at Paris-Sud Medical School (France) in 2007 and completed his Master in Oncology in 2008 at the same university. He is a member of Professor Maha Ayyoub’s laboratory, T2i (anti-tumor immunity and immunotherapy), where he is involved with research into the complexity of microenvironment interactions between the primary tumour and metastases as part of his PhD. Dr Gomez Roca is an active member of ESMO, ASCO and AACR. In addition, he has contributed to more than 60 peer-reviewed publications including publications as first or second author in the Journal of Clinical Oncology and Annals of Oncology. He currently serves as Chair of the Membership Committee (20222023) of ESMO, and he is a member of the ESMO Council and the ESMO-Magnitude of Clinical Benefit Scale Working Group. He also leads the Patient Advocacy Group at the Société Française d’Immuno-Thérapie du Cancer (FITC) since 2019. Dr Gomez-Roca is the lead investigator in Kazia’s phase I study of EVT801 in patients with advanced solid tumours. The study commenced recruitment in Q4 CY2021 and is currently underway at two hospitals in France. Initial data is expected within 12-18 months. Our Collaborators
RkJQdWJsaXNoZXIy MjE2NDg3